Bio-Techne Corporation logo
TECHBio-Techne Corporation

Free Cash Flow (FCF): $269.60M

The free cash flow (FCF) is $269.60M. It is above its 12-month average by 13.21% ($238.14M).

Free Cash Flow

TECH Free Cash Flow (FCF)

$77.58M

Reported quarterly free cash flow; no daily interpolation.

-29.93% 5Y

TECH Quarterly Free Cash Flow Growth (YoY)

Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.

TECH Free Cash Flow (FCF)

TECH Average Free Cash Flow (FCF) Chart

TECH Free Cash Flow (FCF)

TECH Current vs Average Free Cash Flow (FCF) Chart

TECH Free Cash Flow (FCF) Metrics

FREE CASH FLOW (FCF)

$269.60M

FREE CASH FLOW (FCF) AVG TTM

$238.14M

FREE CASH FLOW (FCF) AVG 3Y

$236.96M

FREE CASH FLOW (FCF) AVG 5Y

$251.36M

FREE CASH FLOW (FCF) AVG 10Y

$201.23M

FREE CASH FLOW (FCF) AVG 15Y

$174.13M

FREE CASH FLOW (FCF) AVG 20Y

$154.79M

CURRENT VS TTM AVG

+13.21%

CURRENT VS 3Y AVG

+13.77%

CURRENT VS 5Y AVG

+7.26%

CURRENT VS 10Y AVG

+33.98%

CURRENT VS 15Y AVG

+54.83%

CURRENT VS 20Y AVG

+74.17%

FCF Analysis

Free Cash Flow (TTM)

$269.60M

FCF Yield

2.42%

Price/FCF

41.3

Formula: FCF = Operating Cash Flow - Capital Expenditures

Why FCF matters:

  • Shows actual cash available (not accounting earnings)
  • Funds dividends, buybacks, and debt reduction
  • Less susceptible to accounting manipulation than net income
  • Key metric for DCF valuation models

Free Cash Flow (FCF) Formula & Definition

Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Free Cash Flow (FCF) FAQ

What is the free cash flow (FCF) for Bio-Techne Corporation (TECH)?
The free cash flow (FCF) for TECH stock is $269.60M.
What is the TTM average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
The TTM average free cash flow (FCF) for TECH stock is $238.14M.
What is the 3Y average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
The 3Y average free cash flow (FCF) for TECH stock is $236.96M.
What is the 5Y average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
The 5Y average free cash flow (FCF) for TECH stock is $251.36M.
What is the 10Y average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
The 10Y average free cash flow (FCF) for TECH stock is $201.23M.
What is the 15Y average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
The 15Y average free cash flow (FCF) for TECH stock is $174.13M.
What is the 20Y average free cash flow (FCF) for Bio-Techne Corporation (TECH)?
The 20Y average free cash flow (FCF) for TECH stock is $154.79M.

TECH Free Cash Flow (FCF) History

DATEFREE CASH FLOW (FCF)
2026-03-31$269.60M
2025-09-30$224.06M
2025-03-31$220.75M
2024-09-30$245.03M
2024-03-31$251.15M
2023-09-30$215.41M
2023-03-31$232.73M
2022-09-30$284.52M
2022-03-31$301.92M
2021-09-30$295.16M
2021-03-31$224.58M
2020-09-30$178.53M
2020-03-31$170.31M
2019-09-30$150.96M
2019-03-31$170.97M
2018-09-30$145.27M
2018-03-31$135.37M
2017-09-30$144.08M
2017-03-31$116.62M
2016-09-30$124.87M
2016-03-31$123.87M
2015-09-30$114.35M
2015-03-31$125.07M
2014-09-30$124.98M
2014-03-31$111.76M
2013-09-30$103.13M
2013-03-31$112.75M
2012-09-30$114.14M
2012-03-31$117.85M
2011-09-30$127.25M
2011-03-31$120.82M
2010-09-30$108.80M
2010-03-31$102.90M
2009-09-30$106.20M
2009-03-31$101.62M
2008-09-30$105.58M
2008-03-31$98.70M
2007-09-30$84.35M
2007-03-31$87.20M
2006-09-30$81.98M
2006-03-31$71.04M
2005-09-30$61.42M
2005-03-31$61.88M
2004-09-30$65.93M
2004-03-31$58.86M
2003-09-30$39.79M
2003-03-31$12.85M

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN
3,100 employees
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Kim Kelderman